Skip to main content
Clinical Trials/NCT00259545
NCT00259545
Completed
Phase 2

Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden

Heidelberg University1 site in 1 country60 target enrollmentFebruary 2003

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Ulcerative Colitis
Sponsor
Heidelberg University
Enrollment
60
Locations
1
Primary Endpoint
complete steroid reduction
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

The purpose of this study is to evaluate if retarded release phosphatidylcholine is an effective alternative to steroid dependent or -refractory course in chronic active ulcerative colitis.

The hypothesis is, that ulcerative colitis is caused by a barrier defect of the colonic mucus layer. The background of the study is the finding, that the phosophatidylcholine content of the colonic mucus is strongly reduced in ulcerative colitis (UC) compared to healthy controls and patients with Crohn´s disease. The content was measured in non-inflamed areas of the colon in UC. Thus, we evaluate whether a substitution of colonic PC is an effective method for steroid dependent UC. See: Gut. 2005 Jul;54(7):966-71. Stremmel et al.

Detailed Description

Design: Prospective, randomized, placebo-controlled, double-blinded study. Population: 60 patients with chronic active ulcerative colitis and steroid dependency Inclusion: Chronic active ulcerative colitis, clinical index 5 or more, endoscopic Index 5 or more, steroid dependent course since at least 4 months. Main criteria: complete steroid reduction

Registry
clinicaltrials.gov
Start Date
February 2003
End Date
February 2006
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Signed Letter of Content
  • diagnosis of ulcerative colitis (clinical, endoscopic and histologic evidence)
  • chronic active and steroid dependent course over at least 4 months (CAI \> 4, EAI \> 4)

Exclusion Criteria

  • infectious colitis
  • toxic megacolon
  • ulcerative proctitis or less than 20cm inflamed

Outcomes

Primary Outcomes

complete steroid reduction

Secondary Outcomes

  • remission, life quality, clinical indices, endoscopic indices, histological score, subgroup analysis

Study Sites (1)

Loading locations...

Similar Trials